Limited research on CCL13 in pulmonary fibrosis identifies blood CCL13 levels as a prognostic biomarker in IPF patients treated with placebo versus those treated with pirfenidone [178]. This evidence concerns the gene CCL13 and idiopathic interstitial pneumonia.